Cargando…
Antisense technology: A review
Antisense technology is beginning to deliver on the broad promise of the technology. Ten RNA-targeted drugs including eight single-strand antisense drugs (ASOs) and two double-strand ASOs (siRNAs) have now been approved for commercial use, and the ASOs in phase 2/3 trials are innovative, delivered b...
Autores principales: | Crooke, Stanley T., Liang, Xue-Hai, Baker, Brenda F., Crooke, Rosanne M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005817/ https://www.ncbi.nlm.nih.gov/pubmed/33600796 http://dx.doi.org/10.1016/j.jbc.2021.100416 |
Ejemplares similares
-
Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics
por: Lee, Richard G., et al.
Publicado: (2013) -
Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
por: Geary, Richard S., et al.
Publicado: (2015) -
Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017) -
Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018) -
Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2016)